GGHC
VECT

Gilder Gagnon Howe & Co’s VectivBio Holding AG Ordinary Shares VECT Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VECT Stock Details VECT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-56,137
Closed -$478K – 344
2023
Q1 		$478K Buy
+56,137
New +$463K 0.01% 222

Other funds holding VECT

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gilder Gagnon Howe & Co's VECT Position: Q2 2023 in Review

Gilder Gagnon Howe & Co sold out of VectivBio Holding AG Ordinary Shares (VECT) in Q2 2023, closing a stake of 56,137 shares — an estimated $478K sold.

Gilder Gagnon Howe & Co first reported a position in VECT in Q1 2023 and held it in 1 quarter. The position peaked at $478K in Q1 2023. 49 funds tracked by Wall St. Rank hold VECT as of Q2 2023.

  • Gilder Gagnon Howe & Co reported no remaining VectivBio Holding AG Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 56,137 VectivBio Holding AG Ordinary Shares shares in Q2 2023, an estimated $478K.
  • Gilder Gagnon Howe & Co first reported a position in VectivBio Holding AG Ordinary Shares in Q1 2023 and held it in 1 quarter.
  • Gilder Gagnon Howe & Co's VectivBio Holding AG Ordinary Shares position peaked at $478K in Q1 2023.
  • 49 funds tracked by Wall St. Rank held VectivBio Holding AG Ordinary Shares as of Q2 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2023, filed 14 Aug 2023.